{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-238065","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-10-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.512468+00:00","generated_at":"2026-05-17T03:52:50.314554+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness","bullets":["Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.","Daniel receives $415,900 base salary, 40% target bonus, and 578,000-share stock option grant vesting over 4 years.","Daniel brings 25+ years life-science finance; previously SVP Finance at Bruker Spatial Biology until 2025.","He has managed $400M cash portfolio and executed ~$1B in equity/debt transactions, supporting Atossa's commercial launch of (Z)-endoxifen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-238065","json":"https://secwatch.observer/filing/0001193125-25-238065.json","markdown":"https://secwatch.observer/filing/0001193125-25-238065.md","text":"https://secwatch.observer/filing/0001193125-25-238065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/0001193125-25-238065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/atos-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:52:50.314554+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}